Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Incyte Looks to More Than Double International Business by 2030: CEO
Incyte is targeting a more than twofold expansion of its business outside the US by 2030, with the share of international revenue set to rise from around 10% now to 20%-30%, President and CEO Bill Meury said, underscoring a continued…
To read the full story
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
- Furukawa Resigns as Heartseed Outside Director
September 18, 2026
- Japan Approves Fuji’s New Stelara, Simponi Biosimilar Formulations
September 17, 2026
- Maruishi Clinches Japan Rights to Kringle’s Vocal Fold Scar Drug
September 17, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…